Skin Stripping Bioequivalence Endorsement Expected In FDA Guidance
This article was originally published in The Rose Sheet
Executive Summary
FDA is expected to advocate dermatopharmacokinetics (skin stripping) as a method to determine bioequivalence (BE) of dermatologic drugs in an upcoming guidance document, FDA Office of Pharmaceutical Sciences Senior Research Scientist Vinod Shah, PhD, said.